BRPI0710436A8 - método para determinar se um paciente é portador de hla-b*1502, kit para determinar se um paciente é portador de hla-b*1502,kit de três sondas para determinar se um paciente é portador de hla-b*1502, método para determinar se um paciente é portador de hla-b*5801, kit para determinar se um paciente é portador de hla-b*5801, kit de três sondas para determinar se um paciente é portador de hla-b*5801 e método para determinar se um composto é um candidato que induz uma reação adversa causada por droga (adr) em um paciente que é portador de um alelo de hla associado com a adr induzida por um droga - Google Patents
método para determinar se um paciente é portador de hla-b*1502, kit para determinar se um paciente é portador de hla-b*1502,kit de três sondas para determinar se um paciente é portador de hla-b*1502, método para determinar se um paciente é portador de hla-b*5801, kit para determinar se um paciente é portador de hla-b*5801, kit de três sondas para determinar se um paciente é portador de hla-b*5801 e método para determinar se um composto é um candidato que induz uma reação adversa causada por droga (adr) em um paciente que é portador de um alelo de hla associado com a adr induzida por um droga Download PDFInfo
- Publication number
- BRPI0710436A8 BRPI0710436A8 BRPI0710436A BRPI0710436A BRPI0710436A8 BR PI0710436 A8 BRPI0710436 A8 BR PI0710436A8 BR PI0710436 A BRPI0710436 A BR PI0710436A BR PI0710436 A BRPI0710436 A BR PI0710436A BR PI0710436 A8 BRPI0710436 A8 BR PI0710436A8
- Authority
- BR
- Brazil
- Prior art keywords
- hla
- patient
- kit
- drug
- adr
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 7
- 239000003814 drug Substances 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 3
- 108700028369 Alleles Proteins 0.000 title abstract 2
- 239000000523 sample Substances 0.000 title 2
- 206010067484 Adverse reaction Diseases 0.000 title 1
- 230000006838 adverse reaction Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 abstract 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 abstract 2
- 206010061623 Adverse drug reaction Diseases 0.000 abstract 1
- 206010073508 Drug reaction with eosinophilia and systemic symptoms Diseases 0.000 abstract 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 abstract 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 abstract 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80012106P | 2006-05-11 | 2006-05-11 | |
| US60/800,121 | 2006-05-11 | ||
| PCT/US2007/068782 WO2007134235A2 (en) | 2006-05-11 | 2007-05-11 | Hla alleles associated with adverse drug reactions and methods for detecting such |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI0710436A2 BRPI0710436A2 (pt) | 2012-10-09 |
| BRPI0710436A8 true BRPI0710436A8 (pt) | 2018-06-26 |
Family
ID=38694734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0710436A BRPI0710436A8 (pt) | 2006-05-11 | 2007-05-11 | método para determinar se um paciente é portador de hla-b*1502, kit para determinar se um paciente é portador de hla-b*1502,kit de três sondas para determinar se um paciente é portador de hla-b*1502, método para determinar se um paciente é portador de hla-b*5801, kit para determinar se um paciente é portador de hla-b*5801, kit de três sondas para determinar se um paciente é portador de hla-b*5801 e método para determinar se um composto é um candidato que induz uma reação adversa causada por droga (adr) em um paciente que é portador de um alelo de hla associado com a adr induzida por um droga |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7943309B2 (enExample) |
| EP (1) | EP2016198B1 (enExample) |
| JP (1) | JP2009536828A (enExample) |
| KR (1) | KR101450348B1 (enExample) |
| CN (1) | CN101454462A (enExample) |
| AU (1) | AU2007249225B2 (enExample) |
| BR (1) | BRPI0710436A8 (enExample) |
| CA (1) | CA2651954C (enExample) |
| DK (1) | DK2016198T3 (enExample) |
| ES (1) | ES2422735T3 (enExample) |
| IL (1) | IL194900A (enExample) |
| MY (1) | MY150648A (enExample) |
| NZ (2) | NZ597628A (enExample) |
| PL (1) | PL2016198T3 (enExample) |
| PT (1) | PT2016198E (enExample) |
| TW (1) | TWI335937B (enExample) |
| WO (1) | WO2007134235A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1536021A1 (en) * | 2003-11-27 | 2005-06-01 | Consortium National de Recherche en Genomique (CNRG) | Method for HLA typing |
| US8927462B2 (en) | 2010-04-12 | 2015-01-06 | Academia Sinica | Method for identifying HLA complexes associated with adverse drug reactions |
| WO2012174723A1 (en) * | 2011-06-23 | 2012-12-27 | Chang Gung Medical Foundation Chang Gung Memorial Hospital at Keelung | Risk assessment for phenytoin-induced adverse drug reactions |
| CN102296109A (zh) * | 2011-06-30 | 2011-12-28 | 北京思尔成生物技术有限公司 | HLA-B*1502基因的SYBR Green I检测方法及其专用引物与试剂盒 |
| US20150225788A1 (en) | 2011-12-12 | 2015-08-13 | Wen-Hung Chung | Risk assessment for phenytoin-induced adverse drug reactions |
| CN102660635B (zh) * | 2012-01-14 | 2014-03-12 | 长沙三济生物科技有限公司 | 一种定性检测hla-b*1502基因亚型的荧光pcr试剂盒 |
| CN103114138B (zh) * | 2013-01-27 | 2014-12-03 | 复旦大学 | Pcr-ssp法定性检测hla-b*1502基因的方法及临床试剂盒 |
| CN105722999A (zh) * | 2013-09-17 | 2016-06-29 | 新加坡科技研究局 | 检测遗传变体的方法 |
| CN104017898B (zh) * | 2014-06-25 | 2016-04-27 | 上海荻硕贝肯生物科技有限公司 | 快速检测hla-b*5801等位基因的引物、试剂盒及方法 |
| CN104232781B (zh) * | 2014-09-26 | 2017-04-19 | 陕西佰美基因股份有限公司 | 一种检测HLA‑B*5801等位基因的TaqMan探针实时荧光PCR方法 |
| CN106119362B (zh) * | 2016-06-30 | 2019-09-10 | 江苏伟禾生物科技有限公司 | 一种用于检测hla-b*1502等位基因的引物组及试剂盒 |
| CN108929902B (zh) * | 2018-07-28 | 2022-03-25 | 北京博奥晶典生物技术有限公司 | 用于检测等位基因hla-b*5801的肽核酸引物组合物、试剂盒及方法 |
| CN109355358A (zh) * | 2018-10-22 | 2019-02-19 | 江苏美因康生物科技有限公司 | 一种快速高效检测药源性皮肤不良反应相关基因多态性的试剂盒及方法 |
| CN109554460B (zh) * | 2018-12-17 | 2022-03-22 | 上海市疾病预防控制中心 | 一种基于hla基因多态性位点预测h7n9易感人群的检测方法及其用途 |
| TWI804620B (zh) * | 2019-05-06 | 2023-06-11 | 長庚醫療財團法人林口長庚紀念醫院 | 評估疾病調節抗風濕藥物引發嚴重皮膚藥物不良反應風險的方法、其檢測套組及其用途 |
| US20220259655A1 (en) * | 2019-05-06 | 2022-08-18 | Chang Gung Memorial Hospital, Linkou | Methods for assessing the risk of developing severe cutaneous adverse drug reactions induced by disease-modifying antirheumatic drugs, detection kit thereof and uses thereof |
| CN111620924A (zh) * | 2020-06-04 | 2020-09-04 | 华中农业大学 | 基于天然产物的药物设计方法、五环三萜类化合物、其制备方法及应用 |
| CN113308532A (zh) * | 2021-05-28 | 2021-08-27 | 上海康黎诊断技术有限公司 | 一种用于检测人hla-b*1502基因突变的特异性引物探针组合及其试剂盒，以及方法 |
| WO2023080478A1 (ko) * | 2021-11-02 | 2023-05-11 | 주식회사 랩 지노믹스 | Ｈｌａ－ｂ＊5801 대립유전자 검출용 핵산 분자 및 이를 이용한 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5583238A (en) * | 1990-11-19 | 1996-12-10 | G. D. Searle & Co. | Method for making intermediates useful in synthesis of retroviral protease inhibitors |
| US5883238A (en) * | 1993-03-18 | 1999-03-16 | N.V. Innogenetics S.A. | Process for typing HLA-B using specific primers and probes sets |
| US5550039A (en) | 1995-03-07 | 1996-08-27 | Hoffmann-La Roche Inc. | Oligonucleotide primers for HLA class I B locus DNA typing |
| US6583139B1 (en) | 1997-07-31 | 2003-06-24 | Eugene D. Thorsett | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| BRPI0407569A (pt) * | 2003-02-17 | 2006-02-14 | Novartis Ag | uso de s-10-hidróxi-10, 11-diidro-carbamazepina para o tratamento de ansiendade e distúrbios bipolares |
| US7470513B2 (en) * | 2003-11-10 | 2008-12-30 | Academia Sinica | Risk assessment for adverse drug reactions |
-
2007
- 2007-05-11 ES ES07797432T patent/ES2422735T3/es active Active
- 2007-05-11 CA CA2651954A patent/CA2651954C/en active Active
- 2007-05-11 WO PCT/US2007/068782 patent/WO2007134235A2/en not_active Ceased
- 2007-05-11 DK DK07797432.7T patent/DK2016198T3/da active
- 2007-05-11 US US11/747,674 patent/US7943309B2/en active Active
- 2007-05-11 PL PL07797432T patent/PL2016198T3/pl unknown
- 2007-05-11 BR BRPI0710436A patent/BRPI0710436A8/pt not_active Application Discontinuation
- 2007-05-11 KR KR1020087027562A patent/KR101450348B1/ko active Active
- 2007-05-11 NZ NZ597628A patent/NZ597628A/xx not_active IP Right Cessation
- 2007-05-11 CN CNA2007800170212A patent/CN101454462A/zh active Pending
- 2007-05-11 JP JP2009510183A patent/JP2009536828A/ja active Pending
- 2007-05-11 MY MYPI20084331 patent/MY150648A/en unknown
- 2007-05-11 TW TW096116910A patent/TWI335937B/zh active
- 2007-05-11 NZ NZ572259A patent/NZ572259A/en not_active IP Right Cessation
- 2007-05-11 AU AU2007249225A patent/AU2007249225B2/en not_active Ceased
- 2007-05-11 EP EP07797432.7A patent/EP2016198B1/en not_active Revoked
- 2007-05-11 PT PT77974327T patent/PT2016198E/pt unknown
-
2008
- 2008-10-23 IL IL194900A patent/IL194900A/en active IP Right Grant
-
2011
- 2011-05-04 US US13/100,665 patent/US8142999B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MY150648A (en) | 2014-02-14 |
| ES2422735T3 (es) | 2013-09-13 |
| AU2007249225A1 (en) | 2007-11-22 |
| WO2007134235A3 (en) | 2008-01-17 |
| CA2651954A1 (en) | 2007-11-22 |
| EP2016198B1 (en) | 2013-05-01 |
| DK2016198T3 (en) | 2013-07-15 |
| KR20090031671A (ko) | 2009-03-27 |
| IL194900A (en) | 2013-02-28 |
| AU2007249225B2 (en) | 2013-06-27 |
| CN101454462A (zh) | 2009-06-10 |
| US20080145846A1 (en) | 2008-06-19 |
| WO2007134235A2 (en) | 2007-11-22 |
| KR101450348B1 (ko) | 2014-10-14 |
| TWI335937B (en) | 2011-01-11 |
| CA2651954C (en) | 2014-02-25 |
| IL194900A0 (en) | 2009-08-03 |
| US20110212439A1 (en) | 2011-09-01 |
| NZ572259A (en) | 2012-03-30 |
| EP2016198A2 (en) | 2009-01-21 |
| PL2016198T3 (pl) | 2013-12-31 |
| JP2009536828A (ja) | 2009-10-22 |
| PT2016198E (pt) | 2013-07-29 |
| BRPI0710436A2 (pt) | 2012-10-09 |
| TW200844238A (en) | 2008-11-16 |
| US8142999B2 (en) | 2012-03-27 |
| NZ597628A (en) | 2013-07-26 |
| EP2016198A4 (en) | 2010-07-21 |
| US7943309B2 (en) | 2011-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0710436A8 (pt) | método para determinar se um paciente é portador de hla-b*1502, kit para determinar se um paciente é portador de hla-b*1502,kit de três sondas para determinar se um paciente é portador de hla-b*1502, método para determinar se um paciente é portador de hla-b*5801, kit para determinar se um paciente é portador de hla-b*5801, kit de três sondas para determinar se um paciente é portador de hla-b*5801 e método para determinar se um composto é um candidato que induz uma reação adversa causada por droga (adr) em um paciente que é portador de um alelo de hla associado com a adr induzida por um droga | |
| Alghanim et al. | Detection and evaluation of DNA methylation markers found at SCGN and KLF14 loci to estimate human age | |
| BRPI0416355A (pt) | métodos para avaliar o risco de um paciente desenvolver uma reação adversa a droga, para desenvolver uma terapia para uma reação adversa induzida por uma droga, para avaliar o risco de um paciente desenvolver sjs, ten ou hss, e para identificar uma droga que induz sjs, ten ou hss | |
| Thakker et al. | Genetics of bone biology and skeletal disease | |
| BR112022019754A2 (pt) | Ensaios para detecção de sars-cov-2 | |
| Herbst et al. | Mitochondrial DNA deletion mutations increase exponentially with age in human skeletal muscle | |
| Munafò et al. | Association of the dopamine D4 receptor (DRD4) gene and approach-related personality traits: meta-analysis and new data | |
| Rozek et al. | Epigenetics: relevance and implications for public health | |
| Kinnally et al. | DNA methylation as a risk factor in the effects of early life stress | |
| BRPI1010693A2 (pt) | métodos implementados por computador para marcar e/ou pontuar uma primeira amostra obtida a partir de um sujeito, meios de armazenamento legível em computador de armazenamento de código de programa executável e métodos, sistema e kits de predição de cad em um sujeito | |
| ATE535612T1 (de) | Toxizitätsscreeningverfahren | |
| WO2008069975A3 (en) | Methods of using f-spondin as a biomarker for cartilage degenerative conditions | |
| Becker et al. | Evidence for differences in DNA methylation between Germans and Japanese | |
| BR112014007214A2 (pt) | predição de evento de risco cardiovascular e utilização do mesmo | |
| BR112012026239A2 (pt) | polinucleotídeo isolado, cassete de expressão, célula hospedeira, polipeptídeo isolado, animal transgênico não humano que foi alterado para expressar um polipeptídeo mutante com resistência a alk, anticorpo que se liga especificamente a um polipeptídeo mutante com resistência a alk, kit para detecção de uma mutação com resistência a inibidor de alk em uma amostra biológica, e, métodos para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pelo menos um inibidor de cinase de molécula pequena de alk, para avaliar uma amostra biológica quanto a uma mutação com resistência a inibidor de alk, para diagnosticar um câncer que é resistente a ou é provável que desenvolva resistência a pf-02341066 em um paciente, de reduzir especificamente a expressão de um mutante com resistência a alk, de tratamento de um câncer associado com atividade de alç aberrante que é reistente a pelo mneos um inibidor de cinase de molécula pequena de alk, de traatamento de um câncer aberrante que é resistente a pf-02341066, de identificação de um agente capaz de inibir a atividade cinase de um mutante com resistência a alk ou proteína de fusão de alk | |
| ATE531820T1 (de) | Gesundheitszustandstest | |
| BRPI0519570A2 (pt) | mÉtodo de determinaÇço de faixa de dose de uma warfarina para um indivÍduo, kit para determinaÇço da faixa de dose de uma warfarina, oligonucleotÍdeo ou complemento do mesmo, e, arranjo de oligonucleotÍdeos | |
| Yet et al. | Genetic and environmental impacts on DNA methylation levels in twins | |
| BR112015008042A2 (pt) | diagnósticos complementares para terapia com inibidor de quinase da família tec | |
| BR112022019764A2 (pt) | Ensaios para detecção de sars-cov-2 | |
| WO2008115927A3 (en) | Methods and systems for performing a clinical assessment | |
| Bodden et al. | Impact of varying social experiences during life history on behaviour, gene expression, and vasopressin receptor gene methylation in mice | |
| BRPI0518884A2 (pt) | mÉtodo para medir a resistÊncia ou sensibilidade ao docetaxel | |
| Piniewska-Róg et al. | Impact of excessive alcohol abuse on age prediction using the VISAGE enhanced tool for epigenetic age estimation in blood | |
| Stummann et al. | Embryotoxicity hazard assessment of cadmium and arsenic compounds using embryonic stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: ESCLARECA A DIVERGENCIA ENTRE O NOME DO QUARTO INVENTOR CONSTANTE NA PUBLICACAO INTERNACIONAL WO2007/134235, "CHI-FENG CHANG", E O INFORMADO NA PETICAO DE ENTRADA NA FASE NACIONAL, "CHI-FEN CHANG". |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |